Transcode Therapeutics (RNAZ) Operating Leases (2023)
Transcode Therapeutics' (RNAZ) quarterly Operating Leases came in at $38291.0 in Q4 2023, down 79.82% quarter-over-quarter from $189766.0 in Q3 2023.
Powered by 
Analysis
Transcode Therapeutics (RNAZ) Operating Leases (2023) Analysis & Trends
Transcode Therapeutics (RNAZ) has reported Operating Leases for 1 consecutive years, with $38291.0 the latest figure, recorded in Q4 2023.
- For the quarter ending Q4 2023, Operating Leases changed N/A year-over-year to $38291.0; the trailing twelve-month figure through Dec 2023 stood at $38291.0 (changed N/A YoY), and the FY2023 full-year result was $38291.0, changed N/A from the prior year.
- Operating Leases retreated to $38291.0 in Q4 2023 per RNAZ's latest filing, from $189766.0 in the prior quarter.
- Across five years, Operating Leases topped out at $377813.0 in Q1 2023 and bottomed at $38291.0 in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.67 Bn | 192.69 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.06 Bn | 176.88 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.44 Bn | 123.59 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.94 Bn | 73.95 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.28 Bn | 55.10 Bn | 1.37 Bn |
| 6 | Moderna | 53.87 Bn | 48.73 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.15 Bn | 29.85 Bn | 992.69 Mn |
| 8 | Biogen | 31.88 Bn | 30.60 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.16 Bn | 29.16 Bn | 1.16 Mn |
| 10 | Transcode Therapeutics | 1.70 Mn | 1.70 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 38,291.00 |
| Sep 30, 2023 | 189,766.00 |
| Jun 30, 2023 | 265,652.00 |
| Mar 31, 2023 | 377,813.00 |